RenovaCare products are under development and not approved for sale in the United States.
Results may vary from person to person.

Latest Press Releases

Spray-on Gene Therapy with RenovaCare SkinGun™ in New Study Underway at King’s College London

Roseland, NJ – March 30th, 2020 – RenovaCare, Inc. (Symbol: RCAR; www.renovacareinc.com), developer of patented technologies for spraying self-donated stem cells for the regeneration of skin and other organs and tissues, today announced that the Company’s novel SkinGun™ is now being used to apply regenerative cells in a preclinical study of new gene therapies, underway at King’s College London.  Researchers are using the SkinGun™ to ultra-gently spray gene-supplemented cells for accelerated wound healing in Recessive Dystrophic Epidermolysis Bullosa (RDEB), a debilitating skin disease which afflicts young children and leads to premature death.

Read more

Company Overview

RenovaCare, Inc. is committed to the highest standards of ethical behavior and the Company’s commitment extends to all aspects of its role as an employer and as a corporate citizen. This commitment to ethical behavior extends beyond mere compliance with laws and regulations to inspire our relationships with our shareholders, clients, and employees.

Corporate Office:

RenovaCare, Inc.
94 Hundred Corporate Center,
9375 E Shea Blvd, Suite 107-A
Scottsdale, AZ 85260
1-888-398-0202

Sign Up for Investor Alerts